If you need support, reach out to us
For all four peptides on Thursday's agenda BPC-157, TB-500, KPV, and MOTS-C FDA staff reviewed the evidence under the agency's four-part balancing test and reached the same conclusion for each: do not add them to the 503A Bulk Drug Substances List, the only legal pathway for compounding pharmacies to dispense these compounds to patients
You decide what you want to try
The most common side effect is irritation at the site of injection which could last up to 5-10 minutes
The cost of the initial vial is $200. For batch/lot variance testing, all vials must be identical in every aspectincluding compound, label claim (strength in mg), manufacturer, cap color, and any other distinguishing featuresas the results are combined into a single Certificate of Analysis (COA)